This wiki has undergone a migration to Confluence found Here
BiologicallyDerivedProduct FHIR Resource Proposal
Revision as of 21:34, 9 September 2017 by Kirt Schaper (talk | contribs) (→Contributing or Reviewing Work Groups)
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Example Scenarios
- 1.11 Resource Relationships
- 1.12 Timelines
- 1.13 gForge Users
- 1.14 When Resource Proposal Is Complete
- 1.15 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal
Contributing or Reviewing Work Groups
- Orders and Observations
- Pharmacy
FHIR Resource Development Project Insight ID
Scope of coverage
Substances taken from one biological entity (person, animal, etc) or modifications of such substances, intended to be injected, transplanted or grafted to another (possibly the same) biological entity. This includes but is not limited to:
- blood (whole, extracted cells, plasma, etc)
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
RIM scope
Resource appropriateness
Expected implementations
Content sources
Example Scenarios
Resource Relationships
Timelines
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
